Rocket Pharmaceuticals, Inc. Common Stock (RCKT) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with RCKT
Recent news

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
RCKT

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
RCKT

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
RCKT

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
RCKT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.46
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.02
- SMA 50
- $3.31
- Price below SMA 50
- EMA 50
- $3.17
- Price below EMA 50
- SMA 200
- $3.55
- Price below SMA 200
- EMA 200
- $3.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
RCKT

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
RCKT

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
RCKT

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
RCKT

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
RCKT

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
RCKT

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
RCKT

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
RCKT

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
RCKT

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
RCKT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Rocket Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gaurav D. Shah M.D. | CEO & Director | 1975 |
| Mr. Martin Louis Wilson J.D. | Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | 1976 |
| Mr. Christopher Stevens | Chief Operating Officer | 1981 |
| Mr. Joseph Manhede | Principal Accounting Officer | 1978 |
| Dr. Jonathan Schwartz M.D. | Chief Science & Gene Therapy Officer | 1965 |
| Ms. Meg Dodge J.D., L.L.M. | Senior Vice President & Head of External Affairs | — |
| Ms. Sarbani Chaudhuri M.B.A. | Chief Commercial & Medical Affairs Officer | 1975 |
| Dr. Syed Ali-Aamir Rizvi M.D. | Chief Medical Officer | 1967 |
| Kevin Giordano | Director of Corporate Communications | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 35.46
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.02
- SMA 50
- $3.31
- Price below SMA 50
- EMA 50
- $3.17
- Price below EMA 50
- SMA 200
- $3.55
- Price below SMA 200
- EMA 200
- $3.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $8.60
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.1 | -21.1 | -7.7 | |||||||||
| 2022 | -29.7 | +0.2 | -4.9 | -37.2 | +10.9 | +22.9 | +0.3 | +12.2 | +1.2 | +20.4 | -0.6 | +6.4 |
| 2023 | +13.4 | -12.6 | -15.4 | +0.2 | +14.3 | -5.1 | -9.6 | -12.4 | +28.1 | -6.9 | +22.8 | +28.0 |
| 2024 | -2.6 | +0.4 | -11.8 | -19.5 | -5.4 | -1.8 | +17.1 | -15.2 | +2.6 | -2.7 | -15.3 | -12.8 |
| 2025 | -15.6 | -10.5 | -24.1 | +31.3 | -68.1 | -11.6 | +17.8 | +9.7 | +0.6 | +19.3 | -3.9 | +11.1 |
| 2026 | +0.6 | +44.0 | -28.0 | -3.9 | -13.8 | +13.2 | -11.6 | +9.1 | -29.5 | +1.5 |



